According to TherapeuticsMD's latest financial reports the company's current revenue (TTM) is $1.11 M. In 2022 the company made a revenue of $2.54 M a decrease over the years 2021 revenue that were of $86.95 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $1.95 M | -23.42% |
2022 | $2.54 M | -97.07% |
2021 | $86.95 M | 34.04% |
2020 | $64.87 M | 30.67% |
2019 | $49.64 M | 208.38% |
2018 | $16.09 M | -4.04% |
2017 | $16.77 M | -13.32% |
2016 | $19.35 M | -3.9% |
2015 | $20.14 M | 34.05% |
2014 | $15.02 M | 71.23% |
2013 | $8.77 M | 129.85% |
2012 | $3.81 M | 5.48% |
2011 | $3.61 M | 17676.4% |
2010 | $0.02 M | 92.67% |
2009 | $0.01 M | |
2006 | $1 M | 8.2% |
2005 | $0.92 M | 48.94% |
2004 | $0.62 M | 42.55% |
2003 | $0.43 M | 52.68% |
2002 | $0.28 M | -13.82% |
2001 | $0.33 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Pfizer PFE | $55.09 B | 4,949,855.08% | ๐บ๐ธ USA |
AbbVie ABBV | $54.40 B | 4,887,860.47% | ๐บ๐ธ USA |
Agile Therapeutics
AGRX | $21.49 M | 1,831.27% | ๐บ๐ธ USA |
Royalty Pharma RPRX | $2.23 B | 201,028.57% | ๐ฌ๐ง UK |
Lannett Company LCI | $0.31 B | 27,812.76% | ๐บ๐ธ USA |